Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.48 |
| ▸ | S100A4 | P26447 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13005148 | 0.94 | TRPV1 (0.57) | KDM4EPOLBLMNASMN1; SMN2MAPT | |
| SCHEMBL3967944 | 0.79 | KDM4E (0.58) | KDM4EPOLBLMNASMN1; SMN2MAPT | |
| SCHEMBL3860897 | 0.78 | KDM4E (0.65) | KDM4EPOLBLMNASMN1; SMN2MAPT | |
| SCHEMBL27728031 | 0.78 | KDM4E (0.56) | KDM4EPOLBLMNASMN1; SMN2MAPT | |
| SCHEMBL3773673 | 0.77 | SMN1; SMN2 (0.54) | KDM4EPOLBLMNASMN1; SMN2MAPT | |
| SCHEMBL3777238 | 0.76 | SMN1; SMN2 (0.53) | KDM4EPOLBLMNASMN1; SMN2MAPT | |
| SCHEMBL3771336 | 0.75 | SMN1; SMN2 (0.54) | KDM4EPOLBLMNASMN1; SMN2MAPT | |
| SCHEMBL2800748 | 0.75 | HRH3 (0.63) | KDM4EPOLBLMNASMN1; SMN2HRH3 | |
| SCHEMBL3765979 | 0.75 | SMN1; SMN2 (0.49) | KDM4EPOLBLMNASMN1; SMN2MAPT | |
| SCHEMBL1778495 | 0.74 | KDM4E (0.57) | KDM4EPOLBLMNASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216182-B2 | Carbamate/urea derivatives containing piperidin and piperazin rings as H3 receptor inhibitors | NOVARTIS AG (CH) | 2015-12-22 | — | — | US | claimed |
| US-20140235609-A1 | CARBAMATE/UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS | SHANGHAI CHEMPARTNER CO., LTD (CN) | 2014-08-21 | — | — | US | claimed |
| CN-103917534-A | Carbamate/urea derivatives containing piperidine and piperazine rings as H3 receptor inhibitors | NOVARTIS AG | 2014-07-09 | — | — | CN | claimed |
| WO-2013050987-A9 | CARBAMATE/ UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS | NOVARTIS AG (CH) | 2013-07-25 | — | — | WO | claimed |
| US-9216182-B2 | Carbamate/urea derivatives containing piperidin and piperazin rings as H3 receptor inhibitors | NOVARTIS AG (CH) | 2015-12-22 | — | — | US | disclosed |
| US-20140235609-A1 | CARBAMATE/UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS | SHANGHAI CHEMPARTNER CO., LTD (CN) | 2014-08-21 | — | — | US | disclosed |
| EP-2763978-A1 | CARBAMATE/ UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS | Novartis AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| CN-103917534-A | Carbamate/urea derivatives containing piperidine and piperazine rings as H3 receptor inhibitors | NOVARTIS AG | 2014-07-09 | — | — | CN | disclosed |
| WO-2013050987-A9 | CARBAMATE/ UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS | NOVARTIS AG (CH) | 2013-07-25 | — | — | WO | disclosed |
| WO-2013050987-A1 | CARBAMATE/ UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS | NOVARTIS AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| WO-2007016496-A2 | DIPIPERAZINYL KETONES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235609-A1 | CARBAMATE/UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS | HRH3, HRH4, H1-5 | KDM4E 257/4885POLB 3004/4885LMNA 4236/4885 |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | KDM4E 534/4885POLB 4363/4885LMNA 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.